⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 5, 2026Blood NeoplasiaOpen Access

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia

Uma Borate Cristina E. Tognon Yazan F. Madanat Shikha Misra Andy Kaempf Prapti A. Patel Kara L. Davis Junwei Sun Lucille Stuani Eric D. Eisenmann Christopher A. Eide Stephen E. Kurtz Kevin Watanabe‐Smith Kara Johnson Astraea Jager Stein‐Erik Gullaksen Bridget Robinson Tania Q. Vu Sylvia K. Plevritis Sharyn D. Baker Jessica Minnier Peter Clement Sammantha Avaylon Madison Hayes Laura F. Newell Arpita P. Gandhi Jessica Leonard Brandon Hayes-Lattin Sumi Vasu Rachel J. Cook Gabrielle Meyers Richard T Maziarz Elie Traer Ronan Swords J. Tyner Brian J. Druker Jennifer N. Saultz

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the safety and effectiveness of a drug combination for treating relapsed/refractory acute myeloid leukemia.
Conducted a phase 1 trial with adult patients having relapsed/refractory AML.
Evaluated the safety of Ruxolitinib plus Venetoclax.
Identified potential biomarkers associated with treatment resistance.
The novel combination of Ruxolitinib and Venetoclax is deemed safe for adult patients with R/R AML.
Biomarker CD56 predicts resistance to the combined treatment.
Further investigation is necessary to validate the identified biomarkers' effects.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Tests combination therapy in patients with relapsed/refractory AML, suggesting biomarker implications.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Borate et al. (2026) studied this question.

synapsesocial.com/papers/6a0879bfab15ea61dee8df7c https://doi.org/10.1016/j.bneo.2026.100205

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasmsHuman Clinical Trial · 2026
2Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐AnalysisMeta-Analysis · 2026 · 1 citations
3Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis2025 · 2 citations
4Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosisHuman Clinical Trial · 2026
5Abstract CT191: The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of a Phase I studyEarly-Phase Clinical Trial · 2026
6Trial in progress: A pilot study of venetoclax to AUGMENT epigenetic modification and chemotherapy in pediatric and young adult patients with relapsed and refractory Acute Myeloid Leukemia2025 · 1 citations
7Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study2025 · 3 citations
8The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Early-Phase Clinical Trial · 2026 · 2 citations

More from Stanford University

More from The Ohio State University

More from The University of Texas Southwestern Medical Center

More from Oregon Health & Science University

More from University of Bergen

More from Stanford Medicine

More from Haukeland University Hospital

More from Institute for Stem Cell Biology and Regenerative Medicine